Tag: MindMed - Psilocybin Alpha

New: Psychedelics 2021: A Year in Review

FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder

FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder

Post published:January 25, 2022
Post category:Press Release

MindMed Enrolls First Participant in a Study of its Session Monitoring System

MindMed Enrolls First Participant in a Study of its Session Monitoring System

Post published:January 18, 2022
Post category:Press Release

Stephen Hurst Resigns from MindMed Board of Directors

Stephen Hurst Resigns from MindMed Board of Directors

Post published:January 7, 2022
Post category:Press Release

MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC

MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC

Post published:January 4, 2022
Post category:Press Release

MindMed Announces Transitions to Management Team

MindMed Announces Transitions to Management Team

Post published:December 29, 2021
Post category:Press Release

MindMed Provides Status Update on IND for Phase 2b Trial of LSD for the Treatment of Generalized Anxiety Disorder

MindMed Provides Status Update on IND for Phase 2b Trial of LSD for the Treatment of Generalized Anxiety Disorder

Post published:December 21, 2021
Post category:Press Release

MindMed Initiates Phase 2a LSD Trial for the Treatment of Adult ADHD

MindMed Initiates Phase 2a LSD Trial for the Treatment of Adult ADHD

Post published:December 17, 2021
Post category:Press Release

MindMed Appoints Robert Barrow as Chief Executive Officer and Director

MindMed Appoints Robert Barrow as Chief Executive Officer and Director

Post published:December 14, 2021
Post category:Press Release

MindMed Engages in Productive Pre-Submission Meeting with FDA for Development of the MindMed Session Monitoring System

MindMed Engages in Productive Pre-Submission Meeting with FDA for Development of the MindMed Session Monitoring System

Post published:December 9, 2021
Post category:Press Release

MindMed and Liechti Lab publish first human data on the interacting effects of an SSRI and psilocybin

MindMed and Liechti Lab publish first human data on the interacting effects of an SSRI and psilocybin

Post published:November 30, 2021
Post category:Press Release

End of content

No more pages to load

Psilocybin Alpha

The definitive resource for investors in the emergent psychedelic medicine sector. Cut through the shroom stock noise with exclusive news, interviews, data and private financing opportunities.

Quick Links

Newsletter

Industry insights and interviews delivered to your inbox. No spam, just valuable information.